Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Omeros Corporation (NASDAQ: OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has major impact on a person’s health and life. C3G has two forms: dense deposit ...

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...

True or false: You can improve your C3 glomerulopathy symptoms and your kidney function with a high-sodium diet. National Kidney Foundation: “Complement 3 Glomerulopathy (C3G): Knowing the Signs and ...